Tag: exclusive license agreement

August 21, 2018

Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome

Lixte Biotechnology (OTCQB:LIXT) announced that it has entered into a Clinical Trial Agreement and Exclusive License Agreement with Moffitt Cancer Center to conduct...
June 25, 2018

Aerpio and Gossamer Bio Announce License Agreement

The agreement could bring sales milestones of Aerpio up to US$400 million, including US$20 million as an upfront payment, potential...